TITLE

NEW INDICATIONS

PUB. DATE
July 2007
SOURCE
Drug Topics;7/9/2007, Vol. 151 Issue 13, p42
SOURCE TYPE
Trade Publication
DOC. TYPE
Product Review
ABSTRACT
The article evaluates the Norditropin Injection somatotropin from Novo Nordisk.
ACCESSION #
25886322

 

Related Articles

  • Novo files growth hormone patent infringement suit in US.  // Chemical Market Reporter;10/13/97, Vol. 252 Issue 15, p24 

    Discloses that Novo Nordisk A/S has filed a patent infringement lawsuit in a US District Court against four companies that manufacture and/or market biosynthetic human growth hormones that compete with Novo Nordisk's product in the United States. List of companies cited in the lawsuit; Details...

  • Novo Nordisk to market human growth hormone.  // Drug Topics;1/6/97, Vol. 141 Issue 1, p10 

    Reports on a United States Court of Appeals' decision allowing Novo Nordisk AS to market its recombinant human growth hormone, Norditropin.

  • The 90-Day Launch. Lennox, Mads; Walton, Deborah // Pharmaceutical Executive;Jun2002 Supplement, Vol. 23, p124 

    Presents a case study on the launching of Novo Nordisk's human growth hormone Norditropin. Steps taken by Sentrix Global Health Communications in launching Norditropin; Information on Norditropin; Contribution of the brand icon NordiHero to the launching Norditropin.

  • FDA approves growth hormone.  // Drug Topics;5/22/95, Vol. 139 Issue 10, p8 

    Reports on the Food and Drug Administration's (FDA) approval of Novo Nordisk's growth hormone Norditropin. Drug's indication for the long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.

  • Pharma & Fine Chemicals: Market Briefs.  // Chemical Market Reporter;09/20/99, Vol. 256 Issue 12, p12 

    Presents news briefs from the pharmaceuticals and fine chemicals industries as of September 20, 1999. Acquisition of marketing and distribution rights for Sanofi-Sythelabo's Dynabac in the United States by Muro Pharmaceutical Inc.; Marketing approval received by Nordisk AS for its liquid growth...

  • NEW STORAGE GUIDELINES.  // Drug Topics;2/6/2006, Vol. 150 Issue 3, p52 

    The article reports that Princeton, New Jersey-based Novo Nordisk AS has received new storage guidelines approved by the U.S. Food and Drug Administration. The new storage guidelines are intended for the company's 5- and 10-milligram Norditropin NordiFlex prefilled multi-dose disposable growth...

  • NEW DEVICES.  // Drug Topics;2/6/2006, Vol. 150 Issue 3, p55 

    The article announces the addition of the 10-milligram pen to the line of Norditropin Nordiflex 5-milligram and 10-milligram pens from Novo Nordisk AS in Princeton, New Jersey. The new container size will allow physicians to more closely calculate doses of growth hormone based on weight and age,...

  • Enzyme unit closes.  // Chemical Week;3/6/1996, Vol. 158 Issue 9, p32 

    Reports on the plan of Denmark firm Novo Nordisk to close its manufacturing unit Novo Nordisk Biochemicals K.K. in Hokkaido, Japan. Reasons for the closure; Plans for affected employees.

  • Assisted-living facilities to test insulin-delivery pen. Tarlach, Gemma M. // Drug Topics;3/16/98, Vol. 142 Issue 6, p45 

    Reports that Novo Nordisk's Novolin Prefilled insulin-delivery system will be test marketed by the joint forces of Novo Nordisk Pharmaceuticals, Marriott Senior Living Services, and Medicine-On-Time. Details on the cost effectiveness of pen-style delivery system; Information on how Novo Nordisk...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics